SCB-1019T for Respiratory Syncytial Virus
What You Need to Know Before You Apply
What is the purpose of this trial?
CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability and immunogenicity of SCB-1019T are assessed.
Do I have to stop taking my current medications for the trial?
The trial does not specify if you need to stop taking your current medications. However, it mentions that participants with stable medical conditions can be included, suggesting that you might not need to stop your medications if your condition is stable.
What safety data exists for SCB-1019T or similar treatments for RSV?
What data supports the effectiveness of the drug SCB-1019T for treating Respiratory Syncytial Virus?
Are You a Good Fit for This Trial?
This trial is for healthy adults aged 60-85 who previously received the AREXVY vaccine. Participants must be able to consent, follow the study plan, and have stable pre-existing medical conditions without significant treatment changes or hospitalization in the past 3 months.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either SCB-1019T, AREXVY, or placebo on Day 1
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- SCB-1019T
Find a Clinic Near You
Who Is Running the Clinical Trial?
Clover Biopharmaceuticals USA, LLC
Lead Sponsor